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 Introduction 
 Patients with pre-capillary pulmonary hypertension 
(PH) treated with continuous intravenous prostanoids 
are at risk for bacteremia, bloodstream infections and 
sepsis-related death due to long-term indwelling intrave-
nous central catheters. Proper catheter care and patient 
education are essential in order to prevent infection. Data 
on catheter-related infection (CRI) from individual spe-
cialist centres are limited  [1] . The spectrum of bacterial 
pathogens causing CRI is broad and also differs with the 
prostanoid used  [2–4] .
 In this observational study we report CRI in PH out-
patients treated with continuous intravenous iloprost via 
non-tunnelled central venous catheters and the spectrum 
of causative agents. We discuss the role of rare and pre-
sumptively apathogenic bacteria cultivated.
 Patients and Methods 
 In our PH referral centre we reviewed the medical history of 
CRI from all our patients on continuous intravenous iloprost ther-
apy via non-tunnelled central venous catheters from May 2000 to 
June 2012. All patients gave their written informed consent to have 
their data registered (Swiss PH-registry, approved by the Swiss fed-
eral agency). The diagnosis of PH was established by right heart 
 Key Words 
 Catheter-related infections · Pulmonary hypertension  · 
Prostanoid therapy · Iloprost 
 Abstract 
 Background: Intravenous prostanoid therapy is one corner-
stone of therapy for patients with pre-capillary pulmonary 
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catheterization and was classified according to guidelines  [5] . As 
in other German-speaking centres we used iloprost for severe PH 
needing an intravenous prostanoid  [6] . A central venous catheter 
was directly placed in the subclavian vein without subcutaneous 
tunnelling. Patients were intensively educated in catheter care, 
sterile medication and pump handling. The exit site was always 
covered by sterile transparent wound dressings that were changed 
at least every 5 days after application. In any case of potential infec-
tion (painful, reddish, swollen insertion sight, or any uncertainty) 
patients were instructed to seek specialized medical care immedi-
ately.
 In total we identified 18 PH patients. Three patients were ex-
cluded: 2 due to a tunnelled catheter (Hickman and port system) 
and 1 patient had treatment only during a short pre-mortal inten-
sive care unit stay. The baseline demographics of the included 15 
patients are listed in  table 1 . Follow-up visits after insertion of the 
central venous catheter were done in our centre. Close contact to 
each patient gave us access to the full medical history and data of 
all patients.
 We thoroughly reviewed the medical report of the 15 patients 
for documented or possible CRI. In addition, we checked all mi-
crobiological reports for any positive blood culture or catheter tip 
results in our clinical information system. In cases of uncertainty 
regarding infection, colonization or contamination, we correlated 
the microbiological result with the medical history and decided 
after expert discussion whether the microbiological finding cor-
responds truly with a CRI according to the definition given by the 
centre of disease control  [7] .
 Statistical Analysis 
 Infection rates are reported per 1,000 patient days and annual 
infection rate. Values are reported as the mean and standard de-
viation. All microbiologically positive blood culture and catheter 
tip results are reported and, in case of multiple bacterial growths, 
all identifications are listed separately.
 Results 
 The total number of catheter days was 8,608 with a 
range from 75 to 1,435 days. The mean duration was 
573.9 ± 498.2 days. During the observed time period we 
recorded a total of 11 CRI ( table 2 ). In 4 of the CRI two 
different organisms could be cultured. Nine patients with 
mean treatment duration of 240 ± 132 days never had a 
CRI. Patients with CRI had clinical signs of infection at 
the catheter exit site and/or systemic symptoms  [7] . In all 
cases the catheter was removed and antibiotics therapy 
initiated. The duration of antibiotic therapy depended on 
the severity of infection, ranging from single-shot therapy 
to a treatment duration of maximal 21 days. All the or-
ganisms ever cultivated are listed in  table 3 . In four cul-
tures of the catheter tip only very few colonies were cul-
tivated (3× coagulase-negative staphylococci and 1× 
 Klebsiella pneumoniae ). In the absence of symptoms and 
catheter removal for other reasons these results were 
counted as contamination  [8] . Furthermore, some posi-
tive blood cultures were found without clinical signs of 
CRI and counted as contamination ( Micrococcus luteus , 
 Moraxella , alpha-haemolytic  streptococci and  Coryne-
bacterium ).
 Coagulase-negative  Staphylococcus was associated 
mainly with contamination and found to be responsible 
for only 1 CRI (9%). Rather surprisingly, we noticed a re-
spectable number of cultivations with organisms that are 
usually counted as apathogenic in immunocompetent 
persons:  Brevibacterium (55%, 6 CRI) and  M. luteus (18%, 
Table 1.  Patient demographics
Patients, n 15
Age (mean ± SD), years 47.27 ± 14.0
Female, n 10 (66.7%)
Diagnoses, n
IPAH 8
CTEPH 2
Portopulmonary 1
CTD 4
WHO functional class/NYHA, n
III 6 (40.0%)
IV 9 (60.0%)
6MWD (mean ± SD), m 319 ± 161
 IPAH = Idiopathic pulmonary arterial hypertension; 
CTEPH = chronic thromboembolic PH; Portopulmonary = por-
topulmonary-associated PAH; CTD = connective tissue disease; 
6MWD = 6-min walking distance.
Table 2.  Duration of intravenous prostanoid therapy and encoun-
tered complications (infections, hospitalisations and death)
Duration of intravenous therapy
Total, days 8,608
Mean ± SD, days 573.87 ± 498.24
Max./min., days 1,435/75
CRI
Total 111
Mean per person ± SD 0.73 ± 1.03
Infection rate per 1,000 catheter days 1.28
Annual infection rate ± SD 0.47 ± 0.42
Hospitalisations 10
Ambulatory managed infections 1 (9.1%)
Death related to catheter infection 0
 1 In 4 CRI two etiological organisms could be cultivated.
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2 CRI),  Delftia tsuruhatensis ,  Agrobacterium tumefaciens 
and  Microbacterium aurum . The overall CRI rate in our 
patients was 1.28 per 1,000 catheter days or 0.47 infec-
tions per year, with the majority related to usually apatho-
genic organisms.
 Morbidity and Mortality 
 The 11 CRI led to 10 hospitalizations (91%). We noted 
no death due to ambulatory acquired CRI.
 Discussion 
 In our cohort of PH patients treated with continuous 
iloprost via directly inserted non-tunnelled central ve-
nous catheters we found a low CRI rate in line with re-
ported rates for PH patients treated with prostanoids via 
tunnelled central venous catheters. In contrast to other 
reports, however, the pathogen spectrum in our cohort 
was shifted towards rare and presumed apathogenic or-
ganisms.
 The incidence of CRI in patients with various diseases 
and conditions varies from 0.3 to 9.1 infections per 1,000 
catheter days  [2, 9–11] . In PH patients, relatively low CRI 
rates ranging from 0.1 to 1.13 per 1,000 catheter days for 
tunnelled central venous catheters have been reported 
 [2–4, 12, 13] . Infection rates with treprostinil were found 
to be higher than with epoprostenol  [3] . A single study on 
continuous intravenous iloprost reports a low CRI rate of 
0.41 per 1,000 catheter days  [6] . However, incidence rates 
of different centres vary widely and data on the types and 
course of infections are rare  [3, 13] . Death by catheter-
related sepsis is reported in 4 patients (out of 162) in a US 
 [14] registry and 4 (out of 178) in a French registry  [15] . 
The calculated risk of mortality in these studies is not re-
ported.
 The CRI rate in our collective treated with iloprost via 
non-tunnelled catheters is on the upper limit of the re-
ported rates in PH patients, but still low compared to gen-
eral reports of patients necessitating long-term central ve-
nous catheters. Reasons for different CRI rates may be 
attributed to the patient collective, the insertion tech-
nique of the intravenous line, the pharmacological sub-
stance given, or the method of data collection. In our PH 
collective, intravenous therapy with iloprost was used in 
patients with advanced disease not eligible for transplan-
tation or as a bridge to transplantation according to com-
mon practise in German-speaking countries. With 60% 
of patients being in WHO functional class IV, our pa-
tients were severely ill  [6, 14–17] . The use of direct sub-
clavian catheters without tunnelling has the advantage of 
easy and fast placement and removal of catheters in case 
of therapeutic changes or transplantation. However, a 
tunnelled approach might be more effective in preventing 
CRI  [18] . Since a higher infection rate with treprostinil 
compared to epoprostenol was observed, it was specu-
lated that preparation and storage of drugs contribute to 
an increased incidence of CRI  [4] . For long-term iloprost 
there are no known issues regarding drug handling and 
CRI. Data collection in our study was done by meticu-
lously reviewing every microbiological result and the en-
tire medical histories. However, the systematic approach 
and the interval of data collection might influence the 
published incidence, and the true infection rate might be 
underestimated in some reports.
 An interesting finding of our study is the unexpect-
edly high number of positive results for  Brevibacterium 
spp., causing 6 CRIs in total. The few published cases of 
clinically relevant infections with this bacterium are 
mainly reported in immunocompromised or severely ill 
patients associated with long-term intravenous devices 
 [19–22] .  Brevibacterium is a Gram-positive coryneform 
rod. It is part of the normal flora of skin and adjacent 
structures. Other habitats include raw milk, cheese and 
animal sources. Since cases of bloodstream infections 
Table 3.  Bacterial organisms cultivated in blood cultures or on the 
catheter tip
Organism Cultivations
n
Contaminations
n
CRI positive
n
Brevibacterium spp. 6 6 (54.6)
M. luteus 4 2 2 (18.1)
A. tumefaciens 2 2 (18.1)
Coagulase-negative
Staphylococcus 11 10 1 (9.1)
S. aureus 1 1 (9.1)
M. aurum 1 1 (9.1)
D. tsuruhatensis 1 1 (9.1)
Aeromonas spp. 1 1 (9.1)
Moraxella spp. 2 2
Enterobacter cloacae 1 1
Corynebacterium 2 2
K. pneumoniae 1 1
Alpha-haemolytic 
Streptococcus 1 1
Total 34 19 15 (136.36)1
 Values in parentheses are percentages.
1 In 4 CRI two etiological organisms could be cultivated.
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with this bacterium as the main etiological pathogen have 
been reported in the last 2 decades, the pathogenic poten-
tial of this bacterium, primarily considered to be apatho-
genic, should not be underestimated. All our patients who 
were suffering from CRI with  Brevibacterium reported 
symptoms compatible with infection, namely deteriora-
tion of general condition, malaise, fever and sometimes 
chills. The patients were treated successfully with vanco-
mycin and catheter replacement. In some cases antibiotic 
therapy was escalated with additional moxifloxacin to 
cover possible lower respiratory tract infection.
 It is known that in PH patients treated with intrave-
nous epoprostenol,  Micrococcus spp. is a common etio-
logical pathogen causing CRI  [2, 23, 24] . Similarly, we 
encountered some  M. luteus isolates in PH patients treat-
ed with iloprost. Reasons for this finding are speculative. 
Patient- or disease-related factors seem to be more im-
portant than drug-related factors. Catheter replacement 
and antibiotic treatment resolved the CRI successfully.
 Furthermore, we found very rare pathogens like  A. tu-
mefaciens ( Rhizobium radiobacter ) and  D. tsuruhatensis . 
 A. tumefaciens is an opportunistic pathogen with a low 
virulence. It preferably infects chronically debilitated 
and/or immunocompromised patients with intravascular 
catheters. In a review of 42 combined cases of  Agrobacte-
rium infections, 100% of patients had underlying malig-
nancy or immunocompromising conditions, and 77% 
had indwelling intravascular devices. The authors suggest 
that the pathogens’ capacity to adhere to silicone surfaces 
with extracellular slime contributes to the frequent cor-
relation of infection with indwelling devices  [25] . As PH 
is not thought to lead to immunodeficiency, it remains 
unclear why these cases came to an infection.
 D. tsuruhatensis was first described in 2003 in isolates 
of activated sludge collected from a domestic wastewater 
treatment plant in Japan  [26] . It has been described as a 
plant growth-promoting bacterium. In the literature 
there exists only 1 case report of human infection with 
this bacterium, occurring in a PH patient on intravenous 
prostanoid therapy suffering with a CRI  [27] . The infec-
tion was successfully treated with ciprofloxacin for 21 
days and catheter replacement.
 Conclusion 
 In this first report on severely ill PH patients treated 
with continuous iloprost via non-tunnelled central ve-
nous catheters, we found a relatively low incidence of CRI 
and no associated death. As an interesting finding, we 
could show that uncommon pathogens, some of which 
are counted as apathogenic in non-immunocompro-
mised patients, can be found in a substantial number of 
patients.
 Symptoms of CRI can be unspecific and mild in early 
disease, and therefore clinicians should always be aware 
of possible CRI in these patients. Since progression may 
lead to severe illness and eventually death, treatment and 
replacement of the catheter has to be performed as early 
as possible.
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